ReShape Lifesciences Inc
Research ReShape Lifesciences Inc (HIND) on Bullrun: market cap USD 14.11M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHIND
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 14.11M
- Financial periodQ2 2026
- RevenueUSD 26.96K
- Net income-USD 685.56K
- Free cash flow-USD 903.71K
- Gross margin43.2%
Valuation Snapshot
latest market cap is USD 14.11M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 319.71K | -USD 10.26M | -USD 3.75M | 68.4% | -4.86 | USD 4.98M | USD 31.26K | USD 3.76M |
| FY2024 | USD 8.01M | -USD 1.45M | -USD 614.14K | 2.4% | -6001.39 | USD 101.90K | USD 811.00K | -USD 4.39M |
| FY2023 | USD 8.68M | -USD 11.39M | -USD 17.00M | 63.9% | -110.87 | USD 4.46M | USD 3.02M | -USD 6.17M |
| FY2022 | USD 11.24M | -USD 46.21M | -USD 22.03M | 60.5% | -108.9 | USD 3.86M | USD 2.87M | USD 3.66M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 14.11M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 20.36M | 0.1 | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.26M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.64M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.91M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 47.56M | n/a | n/a | n/a |
About ReShape Lifesciences Inc
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ReShape Lifesciences Inc's market cap?
ReShape Lifesciences Inc's market capitalization is USD 14.11M.
What does ReShape Lifesciences Inc do?
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis.